Study of Lung Health and Microbiome in Adults Aged 35 and Older With and Without HIV in Botswana

What this Trial Is About

Chronic respiratory diseases such as chronic obstructive pulmonary disease COPD cause millions of deaths globally, with many occurring in low- and middle-income countries LMICs. These regions also have high rates of abnormal lung function, including restrictive spirometric pattern RSP, which can precede chronic respiratory diseases and is linked to overall mortality. Sub-Saharan Africa has a large population of people with HIV PWH, and HIV increases the risk of COPD and related deaths, though the mechanisms are not fully understood. This research involves a prospective cohort study in Botswana to describe patterns of abnormal lung function and explore how interactions between the body and microbiome relate to COPD and lung function decline in adults with and without HIV. The study aims to fill knowledge gaps by generating data from Batswana adults, a population disproportionately affected by COPD but underrepresented in research, thus supporting the development of more equitable COPD treatments. Participants aged 35 and older will be observed over five years with assessments including the Duke Activity Status Index DASI and the six-minute walk test to evaluate lung health and function. Data collection will include clinical evaluations, spirometry, and multi-omics analyses to understand host-microbiome relationships. The study involves regular monitoring and follow-up to assess respiratory health outcomes and activity status over time.

Lung Health and the Microbiome Among Adults in Botswana: the Go-hema Cohort